Clinical and prophylactic trials with assured new treatment for those at greater risk: I. A design proposal.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  American Journal of Public Health

• Publication date

  1996-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2105/AJPH.86.5.691PMID 8629721PMCID PMC1380478
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical and prophylactic trials with assured new treatment for those at greater risk: II. Examples.

  1996cited by this paper
• Women resist trials to test marrow transplants.

  1995cited by this paper
• Molecular virology and pathogenesis of hepatitis B

  1993cited by this paper
• A Response to a Purported Ethical Difficulty with Randomized Clinical Trials Involving Cancer Patients

  1992cited by this paper
• Ethical Difficulties with Randomized Clinical Trials Involving Cancer Patients: Examples from the Field of Gynecologic Oncology

  1992cited by this paper
• Ethics and statistics in randomized clinical trials.

  1991cited by this paper
• Of mice but not men. Problems of the randomized clinical trial.

  1991cited by this paper
• Clinical trials--are they ethical?

  1991cited by this paper
• Noncompliance in AIDS research.

  1990cited by this paper
• Design considerations for AIDS trials.

  1990cited by this paper
• Randomization, Statistics, and Causal Inference

  1990cited by this paper
• Practical problems in interim analyses, with particular regard to estimation.

  1989cited by this paper
• Estimating the superiority of a drug to a placebo when all and only those patients at risk are treated with the drug.

  1989cited by this paper
• Effect of crossover on the statistical power of randomized studies.

  1989cited by this paper
• Estimating a treatment effect under biased sampling.

  1988cited by this paper
• Equipoise and the ethics of clinical research.

  1987cited by this paper

• Regression discontinuity design: estimating the treatment effect with standard parametric rate

  2021cites this paper
• SCENTS: Score explained non-randomized treatment systems

  2021cites this paper
• Statistical Modelling for Life-Threatening Diseases

  2020cites this paper
• Noise-Induced Randomization in Regression Discontinuity Designs

  2020cites this paper
• Statistics, data collection and management, and record keeping

  2020cites this paper
• Introduction and overview

  2019cites this paper
• Large-Scale Analysis of Modern Code Review Practices and Software Security in Open Source Software

  2017cites this paper
• Statistical issues in designing and interpreting clinical trials in older adults

  2016cites this paper
• Regression discontinuity designs are underutilized in medicine, epidemiology, and public health: a review of current and best practice.

  2015cites this paper
• Approaches to Mixed Methods Dissemination and Implementation Research: Methods, Strengths, Caveats, and Opportunities

  2015cites this paper
• Regression Discontinuity Design

  2015cites this paper
• Prevention Science: An Epidemiological Approach

  2014cites this paper
• Bayesian regression discontinuity designs: incorporating clinical knowledge in the causal analysis of primary care data

  2014cites this paper
• Commentary: regression discontinuity design: let's give it a try to evaluate medical and public health interventions.

  2014cites this paper
• Analyzing Regression-Discontinuity Designs With Multiple Assignment Variables

  2013cites this paper
• Identification of Treatment Effects on the Treated with One-Sided Non-Compliance

  2013cites this paper
• Continuous evaluation of evolving behavioral intervention technologies.

  2013cites this paper
• Investigating the Accuracy of Three Estimation Methods for Regression Discontinuity Design

  2013cites this paper
• Random Treatment Assignment Using Mathematical Equipoise for Comparative Effectiveness Trials

  2011cites this paper
• The SPELA-Approach to Predictive Modeling

  2011cites this paper
• Clinical trials and rare diseases.

  2010cites this paper
• Treatment research for children and youth exposed to traumatic events: moving beyond efficacy to amp up public health impact.

  2010cites this paper
• Effects of misassignment on bias in the fuzzy regression discontinuity

  2009cites this paper
• E. Regression Discontinuity Design: An Effectiveness-Based Evaluation of Five State Pre-Kindergarten Programs

  2008cites this paper
• Empirical Tests of the Validity of the Regression Discontinuity Design: Implications for its Theory and its Use in Research Practice

  2008cites this paper
• "Waiting for Life to Arrive": A history of the regression-discontinuity design in Psychology, Statistics and Economics

  2008cites this paper
• Alternatives to the randomized controlled trial.

  2008cites this paper
• Empirical Tests of the Validity of the Regression Discontinuity Design (WP-07-02)

  2007cites this paper
• Evaluating disease management programme effectiveness: an introduction to the regression discontinuity design.

  2006cites this paper
• Application of regression-discontinuity analysis in pharmaceutical health services research.

  2006cites this paper
• Baseline Adjustment in Longitudinal Studies

  2005cites this paper
• Experimental designs for multicomponent interventions among persons with multifactorial geriatric syndromes

  2005cites this paper
• New and Dis-Improved: On the Evaluation and Use of Less Effective, Less Expensive Medical Interventions

  2004cites this paper
• Recruiting vulnerable populations for research: revisiting the ethical issues.

  2003cites this paper
• Compound decision theory and empirical bayes methods

  2003cites this paper
• Proposition: the benefit of cardiac transplantation in stable outpatients with heart failure should be tested in a randomized trial.

  2003cites this paper
• A historical perspective on colorectal liver metastases and peritoneal carcinomatosis: similar results, different treatments.

  2003cites this paper
• Mathematical aspects of estimating two treatment effects and a common variance in an assured allocation design

  2002cites this paper
• Cardiac transplantation

  2002cites this paper
• Mechanical cardiac support 2000: current applications and future trial design.

  2001cites this paper
• Regression Discontinuity Design

  2001cites this paper
• Mechanical cardiac support 2000: current applications and future trial design. June 15-16, 2000 Bethesda, Maryland.

  2001cites this paper
• Comparing treatment strategies using a synthesized clinical trial: an analysis of late versus early use of trimethoprim-sulfamethoxazole for AIDS patients

  2001cites this paper
• Mechanical cardiac support 2000: current applications and future trial design: June 15-16, 2000 Bethesda, Maryland.

  2001cites this paper
• Mechanical Cardiac Support 2000: Current applications and future trial design.

  2001cites this paper
• Heart transplantation indicated only in the most severely ill patient: perspectives from the German heart transplant experience

  2001cites this paper
• Placebo control groups in randomized treatment trials: a statistician's perspective.

  2000cites this paper
• References

  1998cites this paper
• [Clinical studies in oncology. Relevance, design, ethical considerations].

  1998cites this paper
• Ethics in clinical research: searching for absolutes

  1998cites this paper
• The cost-benefit of a randomized trial to a health care organization.

  1998cites this paper
• Ethical challenges in efficacy trials of vaginal microbicides for HIV prevention.

  1998cites this paper
• Developing and comparing treatment strategies: an annotated portfolio of designs.

  1998cites this paper
• Feeding artery pressure and venous drainage pattern are primary determinants of hemorrhage from cerebral arteriovenous malformations.

  1998cites this paper
• Klinische Studien in der Onkologie

  1998cites this paper
• Female-controlled methods to prevent sexual transmission of HIV.

  1996cites this paper
• The promise of risk-based allocation trials in assessing new treatments.

  1996cites this paper
• Clinical and prophylactic trials with assured new treatment for those at greater risk: II. Examples.

  1996cites this paper